Solventum Q1 Adjusted EPS Jumps 10.6%, Affirms Outlook; Free Cash Flow Turns Negative
Summary
Solventum reported Q1 2026 adjusted EPS of $1.48, a 10.6% increase year-over-year, and achieved 2.1% organic sales growth. The company also affirmed its full-year 2026 organic sales growth and free cash flow guidance, expecting adjusted EPS towards the high end of its range. However, the quarter saw negative free cash flow of $(273) million and negative operating cash flow. This earnings report is particularly significant given the recent disclosure of activist investor Trian Fund Management's nearly 5% stake, placing increased pressure on the company's financial performance and capital allocation. While the adjusted EPS growth and reaffirmed guidance are positive, the negative cash flow will be a key area of focus for investors and the activist fund.
At the time of this announcement, SOLV was trading at $69.04 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12B. The 52-week trading range was $62.38 to $88.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.